



Said Darwazah, Chairman and CEO of Hikma, awarded Global Generics “Leader of the Year”

London, 13 October 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, is pleased to announce that Said Darwazah, Chairman and Chief Executive Officer of Hikma, received the “Leader of the Year Award” at the Global Generics and Biosimilars Awards held in Barcelona on 4 October 2016. This award recognises his leadership and vision in building Hikma to be a leading global generics and specialty pharmaceutical company.

He commented, “I am delighted and honoured to receive this award. The combined contributions of all of Hikma’s employees across our global markets have helped to drive strong growth and performance and, most importantly, to continue delivering high-quality, affordable generic and branded generic medicines to patients in need.”

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Brooke Clarke, VP Corporate Affairs

+44 (0)20 7399 2770/ +44 7970 338250

FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenue of \$1,440 million and profit attributable to shareholders of \$252 million.